Skip to main content

Does Lantus insulin raise or lower your blood sugar?

Medically reviewed by Melisa Puckey, BPharm. Last updated on June 12, 2024.

Official answer

by Drugs.com

Lantus lowers high blood sugar levels.

Lantus (insulin glargine) is the man made form of a long acting insulin that is given by injection to diabetic patients, to lower their high blood sugar levels.

  • Normally our bodies naturally produce the hormone insulin which works to keep the levels of sugar (glucose) in our blood to the ideal range.
  • People who have diabetes have high blood sugar levels regularly due to their body not producing enough insulin or their body has become resistant to the effect of insulin.
  • Lantus insulin carries the excess blood sugar from your bloodstream and stores it in your body’s tissues to use for energy later on.
  • Lantus lowers the high blood sugar levels that diabetic patients have so that the blood glucose levels are a more normal range.
References

www.drugs.com/pro/lantus.html

Read next

Basaglar and Lantus - What is the difference between them?

Basaglar and Lantus both injections that contain insulin glargine, a long-acting form of insulin to help control blood sugar levels in type 1 and type 2 diabetes. Basaglar is considered a "follow-on" to Lantus but is not a biosimilar, according to the FDA. This means your doctor will need to write a prescription for one or the other as they cannot be substituted at the pharmacy. Continue reading

Toujeo vs Lantus - What's the difference between them?

Both Toujeo and Lantus are long-acting insulins that contain glargine, however Toujeo is more concentrated containing 300 units per mL of glargine, compared to Lantus’s 100 units per mL. When you take this into account the cost of Toujeo and Lantus works out approximately the same (real cost value $30.76/mL for Toujeo compared with $30.23/mL for Lantus). Continue reading

What are biosimilar drugs and how do they compare to biologics?

A biosimilar is a biological product that is similar to a reference biologic (usually the originally approved product) and for which there are no clinically meaningful differences in terms of safety, purity, and potency. One example is Amjevita (adalimumab-atto), the first biosimilar approved for Humira (adalimumab) in 2016. Continue reading

Related medical questions

Drug information

Related support groups